A single arm phase II study of adjuvant anti-PD1 (pembrolizumab) in combination with hormonal therapy in patients with hormone receptor (HR)-positive localized inflammatory breast cancer (IBC) who did not achieve a pathological complete response (pCR) to neoadjuvant chemotherapy

Journal article published in 2018 by Angela Alexander, Jie Willey, Huiming Sun, Charla A. Parker, Angela N. Marx, Anita L. Wood, Sangeetha M. Reddy, James M. Reuben, Roland L. Bassett, Huong T. Le-Petross, Savitri Krishnamurthy, Yun Gong, Wendy A. Woodward, Vicente Valero, Naoto T. Ueno and other authors.

This paper was not found in any repository; the policy of its publisher is unknown or unclear.

Full text: Unavailable

Preprint: policy unknown

Upload

Postprint: policy unknown

Upload

Published version: policy unknown

Upload